{"id":"s6g5t-8","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL267227","moleculeType":"Small molecule","molecularWeight":"314.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sol-Gel Technologies develops proprietary hydrogel-based drug delivery systems for ophthalmic use. S6G5T-8 leverages this platform technology to deliver active pharmaceutical ingredients to the ocular surface with sustained release kinetics, improving bioavailability and reducing dosing frequency compared to conventional eye drops.","oneSentence":"S6G5T-8 is a topical ophthalmic formulation designed to treat dry eye disease by promoting tear production and reducing ocular surface inflammation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:52:34.621Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease"}]},"trialDetails":[{"nctId":"NCT03761810","phase":"PHASE3","title":"A Study of S6G5T3 in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2018-12-14","conditions":"Acne Vulgaris","enrollment":434},{"nctId":"NCT03761784","phase":"PHASE3","title":"A Study of S6G5T-3 in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2018-12-21","conditions":"Acne Vulgaris","enrollment":424},{"nctId":"NCT02661958","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sol-Gel Technologies, Ltd.","startDate":"2016-05","conditions":"Acne Vulgaris","enrollment":726}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vehicle"],"phase":"phase_3","status":"active","brandName":"S6G5T-8","genericName":"S6G5T-8","companyName":"Sol-Gel Technologies, Ltd.","companyId":"sol-gel-technologies-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"S6G5T-8 is a topical ophthalmic formulation designed to treat dry eye disease by promoting tear production and reducing ocular surface inflammation. Used for Dry eye disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}